Your browser doesn't support javascript.
loading
Corrigendum to "Novel oral nano-hepatic targeted anti-PCSK9 in hypercholesterolemia" [Nanomedicine 40 (2022 Feb); 102480. doi: 10.1016/j.nano.2021.102480].
Salaheldin, Taher A; Godugu, Kavitha; Bharali, Dhruba J; Fujioka, Kazutoshi; Elshourbagy, Nabil; Mousa, Shaker A.
Afiliação
  • Salaheldin TA; The Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Rensselaer, NY, USA.
  • Godugu K; The Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Rensselaer, NY, USA.
  • Bharali DJ; The Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Rensselaer, NY, USA.
  • Fujioka K; The Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Rensselaer, NY, USA.
  • Elshourbagy N; Shifa Biomedical Corporation, Malvern, PA, USA.
  • Mousa SA; The Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Rensselaer, NY, USA. Electronic address: shaker.mousa@acphs.edu.
Nanomedicine ; 46: 102602, 2022 Nov.
Article em En | MEDLINE | ID: mdl-36152475
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article